Xenetic Biosciences and Santersus agree to all-stock combination targeting NETs
The companies signed a definitive share exchange agreement expected to close in Q4 2026, creating a Nasdaq-listed firm renamed Santersus Bio, Inc.
SEC filing
Latest
2 stories
Wednesday, September 16
Friday, August 7
Xenetic reports Q2 2026 results, highlights DNase collaboration progress
Xenetic said its DNase platform advanced through outside research partnerships in the quarter, including a partner-run study clearance in Israel, while cash fell to $6.5 million.
SEC filing